No Data
No Data
RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability
Rapt Therapeutics Is Maintained at Neutral by UBS
UBS Maintains RAPT Therapeutics(RAPT.US) With Hold Rating, Cuts Target Price to $2
Express News | RAPT Therapeutics Inc : UBS Cuts Target Price to $2 From $10
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), RAPT Therapeutics (RAPT) and Liquidia Technologies (LQDA)
Barclays Downgrades RAPT Therapeutics(RAPT.US) to Hold Rating, Cuts Target Price to $4
No Data
No Data